H.C. Wainwright Reiterates Their Buy Rating on Caladrius Biosciences

By Ryan Adsit

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Caladrius Biosciences (NASDAQ: CLBS), with a price target of $12. The company’s shares closed yesterday at $5.75.

According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -6.3% and a 34.7% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, RegeneRx Biopharmaceuticals Inc, and Biospecifics Technologies Corp.

Caladrius Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $12.

Caladrius Biosciences’ market cap is currently $54.14M and has a P/E ratio of 2.72. The company has a book value ratio of 1.0152.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Caladrius Biosciences, Inc. operates as a global healthcare company, which engages in developing cellular therapies that repair damaged tissue, cells and organs and restore their normal function. It is pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease.